Marksans Pharma Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Published 3 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹12.3K Cr

The US business is expected to remain a major growth driver, with potential to double revenue in 4-5 years, aiming for around $300 million in 3 years, though geopolitical risks cause some caution. EBITDA margin expected to settle around 19% to 20% range in FY'26, with potential to be slightly better; north of 20% possible but 19%-20% is a safe assumption. - Operating leverage will improve as revenue grows, but initial investments in new markets and infrastructure may increase costs temporarily. - Revenue target to reach Rs.

From Marksans Pharma Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹321

Market Cap

₹12.3K Cr

P/E Ratio

29.4

How does Marksans Pharma Ltd rank in Pharmaceuticals & Biotechnology?

Compare Marksans Pharma Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Marksans Pharma Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹856 Cr, net profit ₹149 Cr.

Full financials →

📊 Revenue & Sales Performance

→The US business is expected to remain a major growth driver, with potential to double revenue in 4-5 years, aiming for around $300 million in 3 years, though geopolitical risks cause some caution.
→The US market opportunity for private label OTC is several billion dollars; Marksans is among the top four players but far behind the market leaders.
→Europe, especially Germany and four other key countries, is targeted for organic growth starting in 2026, with operations expected to scale in the second half of 2026.
→UK market expected to double revenue within 5-7 years with new product launches and improving pricing environment.
→CAPEX planned in 2026 (~Rs. 100 crores) to increase tablet capacity from 700-800 million to 1.2-1.3 billion tablets per month and triple soft gel capacity, enabling revenue growth beyond Rs. 4,000 crores.
→Longer-term revenue target is Rs. 5,000 crores by FY 2030.
→Overall growth rate historically ~20% plus; sustainable EBITDA margins targeted in 19-20%+ range as revenue scales.

📈 Profitability & Margins

→EBITDA margin expected to settle around 19% to 20% range in FY'26, with potential to be slightly better; north of 20% possible but 19%-20% is a safe assumption.
→Operating leverage will improve as revenue grows, but initial investments in new markets and infrastructure may increase costs temporarily.
→Revenue target to reach Rs. 3,000 crores by FY'27 and Rs. 5,000 crores by FY'30, indicating steady long-term growth.
→EPS for H1 FY'26 at Rs. 3.5, with quarterly EPS of Rs. 2.2 in Q2 FY'26, showing growth alongside revenues.
→Growth drivers include strong product pipelines in the U.S., U.K., and Europe, with expectations of improved margins through cost efficiencies and operating leverage.
→Infrastructure expansion planned to support growth beyond Rs. 4,000 crores, including CAPEX of ~Rs. 100 crores in 2026 for capacity enhancement.
→Overall, sustainable EBITDA margin improvement and revenue growth expected, supported by strategic investments and market expansion.

See what Marksans Pharma Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→Planned CAPEX of around ₹100 crores in 2026 to expand tablet capacity at the old Goa plant from 700-800 million to 1.2-1.3 billion tablets per month, also tripling soft gel capacity.
→Expansion focused on acquiring adjacent land and constructing new blocks with shared infrastructure to achieve operating leverage.
→Investment targeted to handle revenue growth beyond ₹4,000 crores and enable scaling towards ₹5,000 crores in the longer term.
→Organic expansion in Europe, especially Germany, with operations starting in FY'26 including hiring employees and infrastructure setup.
→Active pursuit of smaller M&A opportunities across Europe planned for 2026 to complement organic growth.
→Investing in new geographies such as Canada and four European countries, balancing both organic and inorganic growth strategies.
→No current plans to expand manufacturing capacity in the US; focus remains on leveraging low-cost Indian manufacturing base.

💰 Fundraising & Capital Structure

→The document does not mention any current or planned fundraising through debt or equity.
→It states the company continues to remain debt-free, with a cash balance of Rs. 666.5 crore as of September 30, 2025.
→There is a focus on internal cash flows and budgets for CAPEX, such as a planned CAPEX of about Rs. 100 crores in 2026 for capacity expansion.
→No specific plans for raising funds via equity or debt are discussed.
→Future investments, including expansions and acquisitions, appear to be funded through cash on hand and internal accruals.

See what Marksans Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

→Current U.S. order book stands between $225 to $230 million, indicating a strong position. (Page 4)
→The company has ample manufacturing capacity, especially at the Teva plant, currently under 30% utilized, allowing for expansion without immediate capacity constraints. (Page 7)
→Despite tariff uncertainties over the last six months, clarity has recently emerged, improving client confidence and order momentum. (Pages 7, 10)
→The company is targeting an order book of $300 million within three years as part of its growth outlook. (Page 8)
→Growth in other geographies such as Europe and Canada is also expected to contribute to the order pipeline in coming years. (Pages 6, 12)

Key Metrics

What Marksans Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Alivus Life Sciences Ltd (Q2 FY26)
Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores. Key concall takeaways from Alivus Life's Q2 FY26 earnings call — and how it ranks against sector…
Solara Active (Q2 FY26)
Current facility capacity utilization is about 70%, with capacity available to serve new customers. Key concall takeaways from Solara Active's Q2 FY26 earnings…
Sun Pharma.Inds. (Q2 FY26)
India formulation sales grew 11% in Q2, outpacing Indian Pharmaceutical Market (IPM) growth mainly driven by volume and new product launches. Key concall…
Zydus Lifesciences Ltd (Q2 FY26)
Branded formulations in India growing ahead of market at 9% YoY, driven by chronic, cardiology, gynecology, and oncology therapies. Key concall takeaways from…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Marksans Pharma Ltd Q2 FY26 results?

What is Marksans Pharma Ltd share price analysis?

Marksans Pharma Ltd currently shows a neutral. The stock trades at a P/E of 29.4 with a market cap of ₹12,265 Cr. Investors should review the full earnings analysis for detailed insights.

Is Marksans Pharma Ltd planning capital expenditure?

Planned CAPEX of around ₹100 crores in 2026 to expand tablet capacity at the old Goa plant from 700-800 million to 1.2-1.3 billion tablets per month, also tripling soft gel capacity.

Keep Marksans Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.